Found: 2
Select item for more details and to access through your institution.
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial.
- Published in:
- Journal of Inherited Metabolic Disease, 2019, v. 42, n. 3, p. 534, doi. 10.1002/jimd.12080
- By:
- Publication type:
- Article
Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans.
- Published in:
- Journal of Clinical Pharmacology, 2005, v. 45, n. 5, p. 538, doi. 10.1177/0091270004273491
- By:
- Publication type:
- Article